Opioid Abuse Articles & Analysis: Older
6 news found
Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatment Over 142 million opioid prescriptions dispensed in the U.S. in 20201 More than 1.7 million people in the U.S. suffered from substance use disorders related to prescription opioid pain relievers in 20161 BioXcel ...
Loebenberg’s recent notable positions include: president of the Canadian Society for Pharmaceutical Sciences 2014 to 2015; vice chair of the United States Pharmacopeia Dietary Supplement Expert Committee 2016 to 2017; current member of the United States Pharmacopeia Dietary Supplement Expert Committee; current vice chair of the Specialty Committee of Traditional Chinese Medicine in ...
According to recent market research pain following surgery is a $35.5 billion market and is a leading cause of opioid abuse and addiction. The Company is also applying their proprietary delivery platform to several psychedelic and non-psychedelic compounds. ...
Formulated for subcutaneous delivery, Bexson's ketamine-based pain therapy aims to be an alternative to opioids. The patent is directed to Bexson's ketamine formulation that is specifically tuned to the pH and osmolality of subcutaneous tissue, and applies to racemic ketamine, as well as the R or S enantiomers. ...
With his help, the technology we're developing with Stevanato Group has great potential for application beyond our non-opioid BB106 therapy for pain management," said Jeffrey Becker, co-founder and CSO, Bexson Biomedical. ...
Bexson Biomedical, Inc., a research-stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, announced today that they closed a $4.8 million Series A round of financing. Funding will support the company through pre-clinical and GMP manufacturing scale up for its proprietary ketamine formulation, BB106, and the development of a wearable ...